Top Page
Renalytix
(OTC:RENX)
Renalytix (RENX) vs. S&P 500 (SPY)
Renalytix Business Overview & Revenue Model
Renalytix Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 2.37M | 2.29M | 3.40M | 2.97M | 1.49M | 0.00 | Gross Profit |
| 468.00K | 156.00K | 701.00K | 918.00K | 687.00K | -74.00K | EBIT |
| -19.19M | -29.61M | -42.35M | -57.37M | -32.61M | -11.08M | EBITDA |
| -19.98M | -28.52M | -41.71M | -52.69M | -33.69M | -11.08M | Net Income Common Stockholders |
| -23.43M | -33.46M | -45.61M | -45.28M | -34.73M | -9.84M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 9.63M | 4.68M | 26.14M | 44.08M | 74.45M | 14.28M | Total Assets |
| 11.44M | 7.97M | 42.12M | 63.26M | 102.58M | 41.30M | Total Debt |
| 8.21M | 8.54M | 12.15M | 12.71M | 352.00K | 622.00K | Net Debt |
| -1.00M | 3.85M | -12.53M | -28.63M | -64.81M | -12.67M | Total Liabilities |
| 12.81M | 15.83M | 23.66M | 20.09M | 7.48M | 5.34M | Stockholders Equity |
| -1.37M | -7.85M | 18.45M | 43.17M | 95.10M | 35.96M |
| Cash Flow | Free Cash Flow | ||||
| -18.16M | -30.11M | -32.67M | -46.44M | -26.26M | -11.37M | Operating Cash Flow |
| -23.02M | -30.11M | -32.67M | -45.74M | -24.63M | -10.06M | Investing Cash Flow |
| 21.00K | -4.00K | 0.00 | -694.00K | -741.00K | -485.00K | Financing Cash Flow |
| 26.86M | 10.25M | 15.12M | 25.52M | 77.24M | 16.54M |
Renalytix Technical Analysis
Renalytix Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | £94.23M | 191.36 | 0.72% | 0.77% | -1.22% | -92.99% | |
58 Neutral | £15.85M | ― | -8.99% | ― | -20.43% | -104.66% | |
48 Neutral | $6.46B | 1.17 | -48.25% | 2.67% | 19.50% | 0.61% | |
44 Neutral | £74.91M | ― | 9.99% | ― | ― | 70.92% | |
32 Underperform | £26.50M | ― | 425.97% | ― | -4.48% | 61.09% |
Renalytix Earnings Call Summary
Renalytix Corporate Events
Renalytix has reported a 20% quarter-on-quarter revenue growth in Q3, achieving a milestone of processing over 1,000 billable tests in a quarter for the first time. This growth is supported by the onboarding of a large New York-based primary care network and increased direct-to-physician sales efforts. The company remains on track to meet its full-year expectations and plans to expand the distribution of kidneyintelX.dkd through new insurance payors, care networks, and hospital systems.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.
Renalytix’s overall stock score reflects severe financial challenges, including declining revenues, high operating losses, and solvency issues. While technical indicators suggest a bearish trend, recent strategic expansions and investments by UBS Group AG could provide some optimism. However, the current valuation remains unattractive with a negative P/E ratio and no dividend yield, reinforcing cautious investor sentiment.
To see Spark’s full report on GB:RENX stock, click here.
Renalytix PLC announced that UBS Group AG’s trading book holdings in the company have fallen below the 5% threshold, exempting them from further reporting obligations. This change in UBS’s holdings may impact Renalytix’s shareholder composition and could influence market perceptions of the company’s stock.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.
Renalytix’s overall stock score reflects severe financial challenges, including declining revenues, high operating losses, and solvency issues. While technical indicators suggest a bearish trend, recent strategic expansions and investments by UBS Group AG could provide some optimism. However, the current valuation remains unattractive with a negative P/E ratio and no dividend yield, reinforcing cautious investor sentiment.
To see Spark’s full report on GB:RENX stock, click here.
Renalytix PLC has announced that UBS Group AG’s trading book holdings in the company have fallen below 5%, exempting them from reporting obligations. This change in UBS’s holdings could impact Renalytix’s market dynamics and investor perceptions, as it reflects a shift in the investment strategy of a major financial institution.
Renalytix PLC announced a change in major holdings, with UBS Group AG, through its Investment Bank & Global Wealth Management division, acquiring a 5.043592% voting rights stake in the company. This acquisition could potentially influence the company’s strategic decisions and market positioning, reflecting UBS’s confidence in Renalytix’s business model and growth prospects.
UBS Group AG’s trading book holdings in Renalytix PLC have fallen below the 5% threshold, making them exempt from further reporting. This change in holdings may impact Renalytix’s market perception and investor relations, as significant shifts in shareholder composition can influence company strategy and stakeholder confidence.
Renalytix PLC has announced a change in its major holdings, with UBS Group AG acquiring a significant voting rights position of 5.043585% in the company. This acquisition may influence Renalytix’s strategic decisions and reflects UBS’s confidence in the company’s potential growth and market positioning in the healthcare diagnostics sector.
Renalytix has reported strong financial and operational progress in its half-year report for FY25, with revenues of $1.3 million and a significant increase in commercial insurance reimbursed testing revenue. The company has expanded its doctor base and reduced operational costs, demonstrating a 56.5% reduction in administrative expenses. Renalytix is on track to meet or exceed its revenue growth targets, with plans to expand its kidneyintelX.dkd distribution through new insurance payors and care networks. The company’s efforts are supported by Medicare coverage, international clinical guidelines, and a growing number of pharmaceutical collaborations, positioning it well in the precision medicine industry.
Renalytix announced it will release its unaudited interim results for the six months ending December 31, 2024, on March 18, 2025. The company is hosting both online and in-person investor presentations to discuss these results, inviting current shareholders and interested investors to participate. The announcement underscores the company’s commitment to transparency and engagement with stakeholders, as well as its strategic focus on expanding the deployment of kidneyintelX.dkd across the U.S. healthcare system.
Renalytix PLC has announced a significant change in its shareholder structure, with UBS Group AG’s trading book holdings in the company falling below the 5% threshold. This change means that UBS’s holdings in Renalytix are now exempt from reporting obligations, indicating a potential shift in the investment landscape for the company.
Renalytix announced that its kidneyintelX.dkd test has been featured in the Journal of the American Society of Nephrology, highlighting its significance in precision medicine for diabetic kidney disease. The test’s inclusion in the KDIGO guidelines and its role in facilitating personalized care underscores its potential to transform treatment paradigms, especially with new drug approvals like Ozempic for DKD, by providing risk-based treatment pathways that enhance patient outcomes while controlling healthcare costs.
Renalytix PLC announced a significant change in its shareholder structure as UBS Group AG, through its Investment Bank & Global Wealth Management, has reduced its holdings in the company to below 5%. This reduction in UBS’s trading book holdings means they are now exempt from reporting their stake in Renalytix PLC, highlighting a notable shift in investor interests and potential impacts on the company’s market perception.
Renalytix has provided a trading update indicating that it remains on track to meet its financial targets for the fiscal years 2025 and 2026, supported by a significant increase in the number of tests ordered and a successful £11.8m funding round. The company expects to report revenues of $1.3 million for the first half of fiscal year 2025, with continued growth driven by new partnerships and increased sales representative productivity. The expansion includes onboarding a large New York-based primary care network, which has bolstered growth and is expected to encourage further adoption of kidneyintelX.dkd in the coming year.